New heart mapping technique could make VT ablation safer

NCT ID NCT06464315

ENROLLING_BY_INVITATION Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new mapping method for ventricular tachycardia (VT) ablation that avoids purposely triggering VT. Instead, it uses special software to identify slow-conduction areas during normal heart rhythm. The goal is to see if this approach reduces VT recurrence, death, or complications. The study involves 36 Veterans with scar-related VT undergoing clinically indicated ablation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Functional Substrate-Only Mapping (a procedure using isochronal late activation mapping and peak frequency analysis during voltage mapping)
What this could lead to: If successful, this could make VT ablation safer and more effective by avoiding the risks of intentionally triggering dangerous heart rhythms during the procedure.
What could go wrong: This is a small, early-phase study with only 36 participants, so results may not apply to all patients. The new mapping technique may not be as effective as standard methods in preventing VT recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUDDEN CARDIAC DEATH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Death, Sudden, Cardiac sudden arrhythmia death syndrome sudden cardiac arrest ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SUDDEN CARDIAC DEATH VENTRICULAR TACHYCARDIA

Contacts and locations

Locations

VA San Diego Healthcare System, San Diego, CA

San Diego, California, 92161-0002, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.